C Della Corte1, A Mosca1, F Majo2, V Lucidi2, N Panera3, E Giglioni4, L Monti5, L Stronati6, A Alisi3, V Nobili1. 1. Hepato-Metabolic Department, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy. 2. Cystic Fibrosis Unit, Pediatric Department, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy. 3. Liver Research Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy. 4. Emergency Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 5. Liver and Digestive Radiology Unit, Department of Imaging, Bambino Gesu' Children's Hospital, IRCCS, Rome, Italy. 6. Institute of Biology, Molecular Medicine and Nanobiotechnology, CNR, Rome, Italy.
Abstract
OBJECTIVE: The aim of this study was to evaluate the metabolic effects of fatty pancreas (nonalcoholic fatty pancreas disease - NAFPD) in a group of obese paediatric patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We included 121 consecutive children with echographic evidence of hepatic steatosis. All patients underwent to abdominal ultrasound to evaluate pancreatic echogenic pattern. We divided the patients into two groups on the basis of the presence of fatty pancreas. In all patients liver function tests, lipid and gluco-insulinemic profile were evaluated. A selected subset of patients (67) underwent to liver biopsy. RESULTS: Of these 121 patients, 58 showed NAFPD and 63 patients exhibited a normal pancreatic echogenic pattern. No differences were found in age, transaminases serum levels, lipid profile and pancreatic enzymes between the two groups. The patients with NAFPD had a significantly higher z-BMI, fasting insulin, insulin resistance (HOMA-IR) and lower ISI respect to the group without fatty pancreas. The patients with fatty pancreas showed a more advanced form of liver disease, with higher values of fibrosis, ballooning and NAS score with respect to the group without NAFPD. CONCLUSIONS: Our study demonstrated that NAFPD is a frequent condition in obese paediatric patients affected by NAFLD. Our data suggest that pancreatic fat should not be considered an inert accumulation of fat, but as an additional factor able to affect glucose metabolism and severity of liver disease, increasing the risk of develop metabolic syndrome.
OBJECTIVE: The aim of this study was to evaluate the metabolic effects of fatty pancreas (nonalcoholic fatty pancreas disease - NAFPD) in a group of obese paediatric patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We included 121 consecutive children with echographic evidence of hepatic steatosis. All patients underwent to abdominal ultrasound to evaluate pancreatic echogenic pattern. We divided the patients into two groups on the basis of the presence of fatty pancreas. In all patients liver function tests, lipid and gluco-insulinemic profile were evaluated. A selected subset of patients (67) underwent to liver biopsy. RESULTS: Of these 121 patients, 58 showed NAFPD and 63 patients exhibited a normal pancreatic echogenic pattern. No differences were found in age, transaminases serum levels, lipid profile and pancreatic enzymes between the two groups. The patients with NAFPD had a significantly higher z-BMI, fasting insulin, insulin resistance (HOMA-IR) and lower ISI respect to the group without fatty pancreas. The patients with fatty pancreas showed a more advanced form of liver disease, with higher values of fibrosis, ballooning and NAS score with respect to the group without NAFPD. CONCLUSIONS: Our study demonstrated that NAFPD is a frequent condition in obese paediatric patients affected by NAFLD. Our data suggest that pancreatic fat should not be considered an inert accumulation of fat, but as an additional factor able to affect glucose metabolism and severity of liver disease, increasing the risk of develop metabolic syndrome.
Authors: Tawfik Khoury; Akwi W Asombang; Tyler M Berzin; Jonah Cohen; Douglas K Pleskow; Meir Mizrahi Journal: Dig Dis Sci Date: 2017-08-08 Impact factor: 3.199
Authors: Daniel M Tremmel; Austin K Feeney; Samantha A Mitchell; Peter J Chlebeck; Sierra A Raglin; Luis A Fernandez; Jon S Odorico; Sara D Sackett Journal: Am J Transplant Date: 2019-12-16 Impact factor: 8.086
Authors: Selim Kul; Ayşegül Karadeniz; İhsan Dursun; Sinan Şahin; Ömer Faruk Çırakoğlu; Muhammet Raşit Sayın; Turhan Turan; Ahmet Hakan Ateş Journal: Acta Cardiol Sin Date: 2019-03 Impact factor: 2.672